GBT
NASDAQGlobal Blood Therapeutics Inc.
Latest news
25 items- PRDeep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow ShareholdersBelieves Company's Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track's View, Properly Focusing on Heplisav Could Result in More than $1 Billion in Cash Generation by 2030 – More than Dynavax's Current Enterprise Value Sees Shareholder Representation on Board as Necessary to Restore Investor Confidence in Dynavax and Prevent Strategic Blunders Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDA
- PRDeep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual MeetingIssues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom Highlights Concerns that Company's Misguided Acquisition Strategy Will Destroy Value and Prevent Dynavax from Maximizing the Benefit of Heplisav for Shareholders and Patients In Deep Track's View, Focusing on Heplisav Could Result in Nearly $2 Billion of Cash Being Returned to Shareholders by the End of 2030 Details Board's Poor Governance, Reactive Entrenchment Maneuvers, and Unwillingness to Work Constructively Believes Its Slate of Director Nominees Would Collectively Bring Valuable Shareholder Perspective and Independence as Well
- 13D/GSEC Form SC 13G/A filed by Global Blood Therapeutics Inc. (Amendment)SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
- 13D/GSEC Form SC 13G/A filed by Global Blood Therapeutics Inc. (Amendment)SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
- NEWSWhite House Says It Will Continue To Monitor Developments On Cryptocurrencies-Reuters
- SECSEC Form 15-12G filed by Global Blood Therapeutics Inc.15-12G - Global Blood Therapeutics, Inc. (0001629137) (Filer)
- INSIDERSEC Form 4: Patrick Deval L returned 9,037 shares to the company, closing all direct ownership in the company to cover withholding tax4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- INSIDERSEC Form 4: Thompson Alexis A. returned 3,308 shares to the company, closing all direct ownership in the company to satisfy tax liability4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- INSIDERSEC Form 4: Morrison Scott W returned 6,637 shares to the company, closing all direct ownership in the company (tax withholding)4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- INSIDERSEC Form 4: Perry Mark L returned 37,865 shares to the company, closing all direct ownership in the company to satisfy withholding tax4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- INSIDERSEC Form 4: Yarno Wendy L returned 11,437 shares to the company, closing all direct ownership in the company (withholding obligation)4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- INSIDERSEC Form 4: Svoronos Dawn returned 5,376 shares to the company, closing all direct ownership in the company to satisfy withholding obligation4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- INSIDERSEC Form 4: Pizzo Philip A. returned 9,112 shares to the company, closing all direct ownership in the company (withholding tax)4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- INSIDERSEC Form 4: Pierce Glenn returned 26,437 shares to the company, closing all direct ownership in the company to satisfy withholding obligation4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- INSIDERSEC Form 4: Johnson David Lee gifted 22,000 shares and returned 34,384 shares to the company, closing all direct ownership in the company (withholding obligation)4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- INSIDERSEC Form 4: Smith-Whitley Kim returned 5,980 shares to the company, closing all direct ownership in the company to satisfy withholding obligation4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- INSIDERSEC Form 4: Krehlik Carrie returned 6,716 shares to the company, closing all direct ownership in the company (withholding tax)4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- INSIDERSEC Form 4: Habibizad Nazila returned 39,680 shares to the company, closing all direct ownership in the company (for withholding tax)4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- INSIDERSEC Form 4: Love Ted W returned 922,618 shares to the company, closing all direct ownership in the company to satisfy withholding obligation4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- INSIDERSEC Form 4: Choi Jung returned 251,672 shares to the company, closing all direct ownership in the company to cover withholding tax4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- INSIDERSEC Form 4: Farrow Jeffrey S returned 26,739 shares to the company, closing all direct ownership in the company to satisfy withholding tax4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- INSIDERSEC Form 4: Suvari Tricia Borga returned 43,077 shares to the company, closing all direct ownership in the company to cover taxes4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
- SECSEC Form S-8 POS filed by Global Blood Therapeutics Inc.S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
- SECSEC Form S-8 POS filed by Global Blood Therapeutics Inc.S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
- SECSEC Form S-8 POS filed by Global Blood Therapeutics Inc.S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
GBT FAQ
7 questionsWhat does Global Blood Therapeutics Inc. do?
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has...Where does GBT stock trade?
Global Blood Therapeutics Inc. (GBT) is listed on NASDAQ.What sector and industry is GBT in?
Global Blood Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Global Blood Therapeutics Inc. go public?
Global Blood Therapeutics Inc. (GBT) completed its IPO in 2015.What are analysts saying about GBT?
Global Blood Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Mkt Perform on 2022-08-08. Recent price targets cluster around $3100.00.What companies are similar to GBT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GBT side-by-side with any of them on Quantisnow.How can I track GBT on Quantisnow?
Quantisnow aggregates Global Blood Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GBT to receive live email and push alerts on every new disclosure.